NRX PHARMACEUTICALS INC (NRXP) Stock Income Statement
NASDAQ:NRXP - Nasdaq - US6294442099 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 19.70M | 27.59M | 44.34M | 94.43M | 907.40K | |||
| Research and Development | 6.20M | 13.37M | 17.03M | 20.26M | N/A | |||
| Selling, General, and Administrative Expenses | 13.51M | 14.22M | 27.31M | 74.94M | 907.40K | |||
| Operating Income | -19.70M | -27.59M | -44.34M | -94.43M | -907.40K | |||
| Interest Income/Expense | -186.00K | 374.00K | 504.00K | 1.67M | -516.30K | |||
| Other Income/Expense | -4.31M | -2.69M | 4.08M | 20.94M | -660.00K | |||
| Non Recurring Items | -925.00K | -250.00K | 0.00 | -21.25M | 352.10K | |||
| Income Before Taxes | -25.13M | -30.15M | -39.75M | -93.06M | -1.07M | |||
| Income Tax | 0.00 | N/A | 0.00 | 0.00 | 17.80K | |||
| Net Income | -25.13M | -30.16M | -39.75M | -348.88M | -1.09M | |||
| EBITDA | -19.70M | -27.58M | -44.33M | -94.43M | N/A | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -2.36 | -0.40 | -6.04 | -74.36 | -3.98 | |||
| Non GAAP EPS | -2.31 | -4.00 | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD